GlassScriptPhysician profile
Krishnan Srinivasan
NPI 1770579922
$1,880.72
in general payments reported to CMS, 2019-2025
21 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $14.33 · 2021: $60.60 · 2022: $822 · 2023: $107 · 2024: $30.66 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $299.55 | 2022-2025 | Yescarta |
| Lilly USA, LLC | $223.17 | 2022 | |
| Daiichi Sankyo INC. | $197.25 | 2022 | |
| Janssen Biotech, INC. | $177.03 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.80 | 2021-2025 | Opdivo |
| Sirtex Medical INC | $134.91 | 2019 | |
| Glaxosmithkline, LLC. | $119.46 | 2022 | |
| Springworks Therapeutics, INC. | $72.41 | 2025 | Ogsiveo |
| Merck Sharp & Dohme LLC | $72.23 | 2019-2025 | Keytruda, Keytruda Qlex |
| Genentech USA, INC. | $70.00 | 2019-2024 | Tecentriq Hybreza |
| Pfizer INC. | $60.16 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $41.99 | 2025 | Qinlock, Romvimza |
| Gilead Sciences, INC. | $41.40 | 2021-2025 | Trodelvy |
| Abbott Laboratories | $37.79 | 2025 | Mitraclip |
| Genzyme Corporation | $32.42 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.30 | 2021 | |
| Sobi, INC | $27.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.35 | 2019 | |
| Incyte Corporation | $25.94 | 2025 | Jakafi |
| Pacira Pharmaceuticals Incorporated | $18.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnan Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.